BindingDB

The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.5K Targets. Of those, 1.6M data for 765K Compounds and 4.8K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Donate Now

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

Advanced Search

20 articles for DE Ryono

The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Cmpds
Data
Article Title
Organization
10
 
Dual metalloprotease inhibitors. III. utilization of bicyclic and monocyclic diazepinone based mercaptoacetylsEBI
TBA
12
 
Dual metalloprotease inhibitors. II. Effect of substitution and stereochemistry on benzazepinone based mercaptoacetylsEBI
TBA
4
 
Retro-Inverso Tripeptide Renin InhibitorsEBI
TBA
22
Design, synthesis, and structure-activity relationships of piperidine and dehydropiperidine carboxylic acids as novel, potent dual PPARalpha/gamma agonists.EBI
Bristol Myers Squibb
16
 
1,4-substituted indoles: a potent and selective class of angiostensin II receptor antagonistsEBI
TBA
25
Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453).EBI
Bristol Myers Squibb
1
 
Orally active prodrugs of quinoline-4-carboxylic acid angiotensin II receptor antagonistsEBI
TBA
12
 
Quinoline-4-carboxylic acids as angiotensin II receptor antagonistsEBI
TBA
24
 
Diol sulfonamides: A potent and novel class of inhibitors of human reninEBI
TBA
22
Design, synthesis and structure-activity relationships of azole acids as novel, potent dual PPAR alpha/gamma agonists.EBI
Bristol Myers Squibb
24
Discovery of tertiary aminoacids as dual PPARalpha/gamma agonists-I.EBI
Bristol Myers Squibb
14
A new class of high affinity thyromimetics containing a phenyl-naphthylene core.EBI
Pharmaceutical Research Institute
5
Design and synthesis of N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5- methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine [Muraglitazar/BMS-298585], a novel peroxisome proliferator-activated receptor alpha/gamma dual agonist with efficacious glucose and lipid-lowering activities.EBI
Bristol Myers Squibb
26
Discovery of a Partial Glucokinase Activator Clinical Candidate: Diethyl ((3-(3-((5-(Azetidine-1-carbonyl)pyrazin-2-yl)oxy)-5-isopropoxybenzamido)-1EBI
Bristol Myers Squibb
8
Vasopeptidase inhibitors: incorporation of geminal and spirocyclic substituted azepinones in mercaptoacyl dipeptides.EBI
The Bristol-Myers Squibb Pharmaceutical Research Institute
19
Dual metalloprotease inhibitors. 6. Incorporation of bicyclic and substituted monocyclic azepinones as dipeptide surrogates in angiotensin-converting enzyme/neutral endopeptidase inhibitors.EBI
Bristol Myers Squibb
15
alpha-Hydroxy phosphinyl-based inhibitors of human renin.EBI
Bristol Myers Squibb
58
N-(heteroaryl)-sulfonamide derivatives useful as S100-inhibitorsBDB
Active Biotech
16
Pyridine derivatives as soft rock inhibitorsBDB
Redx Pharma
23
Evaluation and comparison of 3D-QSAR CoMSIA models for CDK1, CDK5, and GSK-3 inhibition by paullones.BDB
Universitat Hamburg